Lobe Sciences Strengthens Board with Appointment of Nick Karakochuk

Lobe Sciences Ltd., a Vancouver-based biopharmaceutical company, has appointed Nick Karakochuk to its Board of Directors. The company, listed on the CSE (LOBE), OTCQB (LOBEF), and FWB (LOBE.F), aims to enhance its governance and capital markets expertise through this strategic addition. Mr. Karakochuk, a lawyer specializing in mergers and acquisitions, brings a wealth of experience in corporate governance and securities regulations.

CEO Dr. Frederick D. Sancilio expressed confidence in the timing of this appointment, highlighting the importance of Karakochuk's expertise as the company focuses on disciplined execution in 2026. The appointment aligns with Lobe Sciences' strategy to build on its fiscal 2025 progress.

Mr. Karakochuk receives 3,500,000 restricted share units as part of the company's equity incentive plan. This move reflects Lobe Sciences' commitment to advancing therapies for diseases with unmet medical needs.